MEDI8968 + Saline
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hidradenitis Suppurativa
Conditions
Hidradenitis Suppurativa
Trial Timeline
May 1, 2013 → Oct 1, 2014
NCT ID
NCT01838499About MEDI8968 + Saline
MEDI8968 + Saline is a phase 2 stage product being developed by AstraZeneca for Hidradenitis Suppurativa. The current trial status is terminated. This product is registered under clinical trial identifier NCT01838499. Target conditions include Hidradenitis Suppurativa.
What happened to similar drugs?
1 of 20 similar drugs in Hidradenitis Suppurativa were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01838499 | Phase 2 | Terminated |
Competing Products
20 competing products in Hidradenitis Suppurativa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 41 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 41 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 38 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 38 |
| Sonelokimab (M1095) + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 29 |
| Eltrekibart + Placebo | Eli Lilly | Phase 2 | 39 |
| Placebo + LY3041658 | Eli Lilly | Phase 2 | 35 |
| Placebo + Adalimumab | AbbVie | Approved | 43 |
| Lutikizumab + Placebo | AbbVie | Phase 3 | 47 |
| Adalimumab | AbbVie | Pre-clinical | 26 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 47 |
| adalimumab + placebo | AbbVie | Phase 3 | 40 |
| Lutikizumab | AbbVie | Phase 2 | 42 |
| adalimumab | AbbVie | Phase 3 | 40 |
| Lutikizumab + Placebo | AbbVie | Phase 2 | 39 |
| Risankizumab + Placebo for risankizumab | AbbVie | Phase 2 | 35 |
| adalimumab | AbbVie | Phase 3 | 40 |
| adalimumab + placebo | AbbVie | Phase 3 | 40 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 35 |
| Anifrolumab | AstraZeneca | Phase 2 | 39 |